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Aim: In this post hoc analysis of the EDGE study, we assessed the effectiveness and safety of
vildagliptin versus other oral antidiabetes drugs (OADs) as add-on to ﬁrst-line sulphonylurea
(SU) therapy in patients who did not receive metformin in a real-life setting.
Methods: The primary endpoint was odds of achieving an HbA1c reduction of >0.3% without
tolerability issues. Secondary endpoint was odds of achieving HbA1c <7.0% without hypo-
glycaemia or weight gain. Changes in HbA1c, body weight; and safety were also assessed.
Results: 2936 patients received vildagliptin and 820 received comparator OADs (any -GI,
TZD, glinide) as add-on to ﬁrst-line SU therapy. Overall, the mean age, disease duration,
HbA1c, and BMI at baseline were 57.1 years, 6.3 years, 8.5%, and 27.7 kg/m2, respectively.
The odds ratios for achieving primary and secondary endpoints were 1.6 (95% CI: 1.36, 1.86;
p<0.0001) and 1.8 (1.45, 2.21; p<0.0001), respectively, in favour of vildagliptin. The between-
treatment differences (vildagliptin vs. comparator OAD) for the mean change in HbA1c and
body weight were −0.2±0.04% (p<0.0001) and −0.8±0.16kg (p<0.0001), respectively. Over-
all, the incidence of adverse events was low (vildagliptin, 7% vs. comparator, 8.2%) in both
groups. Similar resultswere observed in a subset of patients enrolled from India andpatients
who received TZDs as a comparator OAD.Conclusion: Under real-life
glycaemic response witho
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. Introduction
uidelines formanagement of type 2 diabetesmellitus (T2DM)
ecommend metformin as the ﬁrst-line treatment unless
ontraindicated, followed by a stepwise intensiﬁcation with
ther oral antidiabetes drugs (OADs) aimed at maintaining
lycated haemoglobin (HbA1c) levels <7.0% [1,2]. In patients
ho are intolerant (gastrointestinal [GI] disturbances) or con-
raindicated (renal impairment, congestive heart failure) to
etformin, sulphonylureas (SUs) are often still the preferred
rst-line treatment option [3]. Additionally, in countries such
s India, SUs are frequently prescribed as ﬁrst-line treatment
ue to their efﬁcacy and low economic burden, particularly in
ean patients [4].
Although SUs have good initial efﬁcacy in recently diag-
osed patients, they are often associated with higher rate
f secondary failure [5], which eventually leads to addition
f other OADs to maintain glycaemic control. Several OADs
ther than metformin, such as -glucosidase inhibitors (-
I), glinides, thiazolidinediones (TZDs), dipeptidyl peptidase
DPP)-4 inhibitors, or sodium-glucose cotransporter (SGLT)-2
nhibitors, are now available for use as add-on. However, an
dd-on should be selected considering patient’s characteris-
ics (clinical proﬁle, co-morbidities, and personal preferences)
nd safety proﬁle (hypoglycaemia and weight gain) of various
ADs. New therapeutic drug classes such as DPP-4 inhibitors
ould offer solutions for some of the challenges physicians
ace in clinical practice while intensifying treatment. The
ombination therapy of a SU (increases insulin secretion) and
DPP-4 inhibitor (increases insulin secretion and modulates
lucagon secretion in a glucose-dependent manner) targets
ultiple pathophysiological defects of T2DM [6–8]. In addi-
ion, DPP-4 inhibitors by themselves do not increase the risk
f hypoglycaemia [7,9].
The Effectiveness of Diabetes control with vildaGliptin and
ildagliptin/mEtformin (EDGE) study was a large, 1-year, real-
ife, observational study, which assessed the effectiveness
nd safety of adding a DPP-4 inhibitor (vildagliptin) vs. other
ADs (metformin; any SU, TZD, -GI or glinide) in 45,868
atients with T2DM inadequately controlled on monotherapy
10]. Physician could prescribe any add-on agent to fail-
ng monotherapy and accordingly patients were assigned to
ildagliptin cohort or other OAD cohort. As expected, majority
approximately 82%) of the patients enrolled in the EDGE study
ere on ﬁrst-line therapy with metformin. The overall results
vildagliptin+ﬁrst-line therapy vs. other OADs+ﬁrst-line ther-
py) and results of the sub analysis (vildagliptin+metformin
s. SU+metformin) are already published [10,11]. However, to
ate, limited evidence is available to guide physicians’ choice
f a second-line OAD after SU monotherapy failure in patients
ho cannot receive metformin. Therefore, it is of clinical
mportance to investigate the effectiveness and safety of var-
ous OADs as add-on to SU monotherapy.
The pragmatic design of the EDGE study and the large
nrolled population at the time when DPP-4 inhibitors were
aunched as a new therapeutic alternative offered an unique
pportunity to explore the real-world effectiveness and safety
f a DPP-4 inhibitor vs. comparator OADs (any -GI, TZD, glin-
de) in patients failing on SU monotherapy and who did not0 ( 2 0 1 6 ) 452–458 453
receive metformin. The current exploratory post hoc analysis
included the overall EDGE population and patients enrolled
from India.
2. Methods
2.1. Study design and patients
EDGE was a 1-year, prospective, observational study con-
ducted in 27 countries. The study design and patient
inclusion/exclusion criteria are extensively described else-
where [10]. In brief, patients aged >18 years who were
inadequately controlled on OAD monotherapy and were pre-
scribed an additional OAD by their physician were included
in the study. The choice of add-on therapy was at the physi-
cian’s discretion. To avoid bias in the selection of second OAD,
enrolment was conﬁrmed after the patients were prescribed
the add-on therapy. All the patients provided consent for data
collection. Patients were assigned to one of two groups: DPP-4
inhibitor (vildagliptin) or comparator (metformin; anySU, TZD,
glinide or -GI). This exploratory analysis included patients
(overall and India) inadequately controlled on SU monother-
apy and who were prescribed an add-on OAD other than
metformin. Data were collected at baseline and at any point
during the 1-year observation period, with a compulsory visit
at month 12.
2.2. Study assessments
The primary effectiveness endpoint of this post hoc analysis,
as in the original protocol, was the proportion of patients
achieving a clinically relevant reduction in HbA1c, deﬁned
as a drop of >0.3%, without any tolerability ﬁndings (hypo-
glycaemia, discontinuation due to GI side effects, peripheral
oedema or weight gain [≥5%]). The secondary effectiveness
endpointwas the composite of glycaemic response, deﬁned as
achievingHbA1c <7.0%,without hypoglycaemia orweight gain
≥3%. Changes in HbA1c and body weight from baseline to the
end of the 12-month observation period were also assessed.
Safety assessments included recording incidence and severity
of all adverse events (AEs) as well as their relationship to the
treatment.
2.3. Statistical analysis
All analyseswere conducted for the intention-to-treat popula-
tion,which included patientswho received at least one dose of
the new add-on agent. Baseline and safety data were descrip-
tively summarised for both groups. Odds ratios (ORs) and
95%conﬁdence intervals (CIs)were calculatedusingmultivari-
able logistic regression models for the primary and secondary
effectiveness endpoints. The OR expresses odds in favour of
success (patients achieving endpoints) with vildagliptin rel-
ative to comparators. As this analysis was not prespeciﬁed
in the protocol, only unadjusted ORs are presented. Changes
in HbA1c and body weight were analysed using analysis of
covariance (ANCOVA) model and were adjusted for covariates
(treatment arm and the respective baseline clinical character-
istics). Approximately 40% of patients included in this post hoc
454 pr imary care d iabetes
Patients from India
(N=1252)
Patients on background SU
monotherapy* (N=3756)
Vildagliptin
(N=2936)
Comparator (N=820)
TZDs (n=536)
   α-GIs (n=218)
   Glinides (n=66)
Patients from India (N=302)
TZDs (n=214)
   α-GIs (n=66)
   Glinides (n=22)
*Patients enrolled in the EDGE study on prior treatment with SU monotherapy
α-GIs, alpha glucosidase inhibitors; SUs, sulphonylureas; TZDs, thiazolidinediones
study in >0.5% of patients, listed by primary system organFig. 1 – Flow chart depicting patient disposition.
analysis were enrolled from India and >65% in the comparator
arm were on TZDs, and thus, as part of sensitivity analyses, all
the statistical analyseswere alsoperformed inboth Indianand
TZDsubsets. All statistical analyseswereperformedusing SAS
software, version 9.3 (SAS Institute Inc., Cary, North Carolina,
USA).
3. Results
3.1. Patient disposition and baseline demographics
Of the 45,868 patients enrolled worldwide, 3756 (n=1554;
Indian subset) were receiving SU monotherapy. Upon treat-
ment intensiﬁcation, 2936 patients received vildagliptin
(n=1252; Indian subset) and 820 (n=302; Indian subset)
received comparators as add-on. The most widely prescribed
add-on to SU monotherapy in the comparator group was
TZD (n=536) (Fig. 1). Patient demographics and baseline char-
acteristics are summarised in Table 1. In general, patients
from India (53.3±9.76 years) were younger than the overall
Table 1 – Demographics and baseline characteristics of the over
Overall
SU+vildagliptin
n=2936
SU+comparatora
n=820
To
n=
Age, years 56.7±11.22 58.9±12.31 57.1
Gender
Men, n (%) 1586 (54.0) 412 (50.2) 199
Women, n (%) 1350 (46.0) 408 (49.8) 175
Weight, kg 75.9±14.60 72.2±14.51 75.1
BMI, kg/m2 27.9±4.59 26.8±4.47 27.7
HbA1c, % 8.5±1.37 8.3±1.37 8.5
T2DM duration, years 6.1±5.37 6.7±5.97 6.3
Values are presented as mean±SD or n (%).
Weight data were missing for 133 and 67 patients; BMI data were missin
patients in the overall and Indian subset, respectively.
a Comparator includes any TZD, -GI or glinide.
-GI, alpha glucosidase inhibitor; BMI, body mass index; OAD, oral antidia
diabetes mellitus.1 0 ( 2 0 1 6 ) 452–458
population (57.1±11.5 years), had been diagnosed with
T2DM in their late 40’s vs. early 50’s (disease duration:
5.5±4.87 vs. 6.3±5.51 years), had lower BMI (26.3±4.01 vs.
27.7±4.59kg/m2), and had higher baseline HbA1c (8.7±1.16%
vs. 8.5±1.38%).
3.2. Overall results
The ORs for achieving the primary and secondary effective-
ness endpoints are presented in Table 2. A higher proportion
of patients in the vildagliptin group vs. the comparator group
(59.8% vs. 48.3%) achieved HbA1c reduction of >0.3% with-
out any predeﬁned tolerability issues. The unadjusted OR was
1.6 (95% CI: 1.36, 1.86; p<0.0001) in favour of the vildagliptin
group. The OR was 1.5 (95% CI: 1.21, 1.75; p<0.0001) for the
vildagliptin group compared with the patients who were pre-
scribed TZDs. Moreover, 28.7% and 18.4% of patients in the
vildagliptin and comparator groups, respectively, reached the
clinically relevant composite endpoint of HbA1c <7.0%, with-
out hypoglycaemia or weight gain ≥3% [OR 1.8 (95% CI: 1.45,
2.21; p<0.0001)]. The corresponding OR vs. patients who were
prescribed TZD was 1.7 (95% CI: 1.35, 2.20; p<0.0001). After 1
year of treatment, the adjusted mean reduction in HbA1c was
−1.4% for the vildagliptin group and −1.2% for the compara-
tor group, with a mean between-group difference of −0.2%
(p<0.0001). The adjusted mean body weight reduction was
higher in the vildagliptin group (−1.1 kg) than in the compara-
tor group (−0.3 kg), with a between-treatment difference of
−0.8 kg (p<0.0001) (Fig. 2). The between-treatment difference
in weight change vs. TZDs was −1.4 kg (p<0.0001).
The incidence of total AEs was low in general; the inci-
dence was lower in the vildagliptin group compared with
the comparator group (vildagliptin: 7.0%, n=204; comparator:
8.2%, n=67). The incidence of AEs in patients who were pre-
scribed TZDs was 5.2% (n=43). AEs that occurred during theclass (SOC), are summarised in Table 3. The most commonly
reported AEs by primary SOC in both groups were GI disorders,
infections and infestations. The overall incidence of hypogly-
all population and the Indian subset.
Indian subset
tal
3756
SU+vildagliptin
n=1252
SU+comparatora
n=302
Total
n=1554
±11.50 53.2±9.62 53.7±10.31 53.3±9.76
8 (53.2) 741 (59.2) 164 (54.3) 905 (58.2)
8 (46.8) 511 (40.8) 138 (45.7) 649 (41.8)
±14.66 70.6±11.40 66.9±11.40 69.9±11.49
±4.59 26.6±3.96 25.4±4.12 26.3±4.01
±1.38 8.7±1.18 8.5±1.05 8.7±1.16
±5.51 5.5±4.84 5.4±4.99 5.5±4.87
g for 134 and 67 patients; HbA1c data were missing for 203 and 99
betes drug; SU, sulphonylurea; TZD, thiazolidinedione; T2DM, type 2
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Table 2 – Proportion of patients achieving primary and secondary effectiveness endpoints in the overall population and
the Indian subset.
Overall Indian subset
SU+vildagliptin
n=2936
SU+comparatora
n=820
SU+vildagliptin
n=1252
SU+comparatora
n=302
Primary effectiveness endpoint (HbA1c drop of >0.3% without any tolerability issuesb)
Success,d n (%) 1755 (59.8) 396 (48.3) 813 (64.9) 173 (57.3)
Unadjusted ORc (95% CI; p value) 1.59 (1.36, 1.86; p<0.0001) 1.38 (1.07, 1.78; p=0.0134)
Secondary effectiveness endpointe (HbA1c <7.0% without hypoglycaemia or ≥3% weight gain)
Success,d n (%) 744 (28.7) 127 (18.4) 235 (20.5) 31 (11.6)
Unadjusted ORc (95% CI; p value) 1.79 (1.45, 2.21; p<0.0001) 1.97 (1.32, 2.94; p=0.0009)
a Comparator includes any TZD, -GI or glinide.
b Tolerability issues: hypoglycaemia, weight gain (≥5%), peripheral oedema, discontinuation due to gastrointestinal events.
c Patients with missing endpoint values of HbA1c or weight (non-evaluable) were considered as failures for calculating OR.
d Patients achieving endpoint.
e In patients with baseline HbA1c ≥7.0%.
-GI, alpha glucosidase inhibitors; OR, odds ratio; SU sulphonylurea; TZD, thiazolidinedione.
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Fig. 2 – Adjusted mean change in HbA1c (A and B) and body weight (C and D) from baseline to endpoint (intention-to-treat
population).
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Table 3 – Adverse events (≥0.5%) by primary system organ class in the overall population and the Indian subset.
Primary system organ class, n (%) Overall Indian subset
SU+vildagliptin
n=2936
SU + comparatora
n=820
SU + vildagliptin
n=1252
SU + comparatora
n=302
Any primary system organ class 204 (6.95) 67 (8.17) 69 (5.51) 31 (10.26)
Gastrointestinal disorders 50 (1.70) 14 (1.71) 24 (1.92) 6 (1.99)
General disorders and administration site conditions 27 (0.92) 12 (1.46) 16 (1.28) 8 (2.65)
Infections and infestations 46 (1.57) 15 (1.83) 7 (0.56) 4 (1.32)
Metabolism and nutrition disorders 33 (1.12) 12 (1.46) 14 (1.12) 8 (2.65)
Musculoskeletal and connective tissue disorders 16 (0.54) 6 (0.73) 4 (0.32) 3 (0.99)
Nervous system disorders 37 (1.26) 4 (0.49) 11 (0.88) 3 (0.99)
Respiratory, thoracic and mediastinal disorders 5 (0.17) 4 (0.49) 0 (0.00) 2 (0.66)
Adverse events (AEs) were coded according to MedDRA version 14.0. A patient with multiple occurrences of an AE in one group is counted only
once in the AE category.
a Comparator includes any TZD, -GI, or glinide.
gulato-GI, alpha glucosidase inhibitor; MedDRA, Medical Dictionary for Re
caemic events was low: 0.9% (n=27) in the vildagliptin group
and 1.2% (n=10) in the comparator group. The incidence of
severe hypoglycaemia was 0.2% (n=6) and 0.4% (n=3) in the
vildagliptin and comparator groups, respectively. The inci-
dences of hypoglycaemia and severehypoglycaemiawere 1.5%
(n=8) and 0.6% (n=3), respectively in patients who received
TZDs.
3.3. Indian subset
Similar to the results in the overall population, vildagliptin
showed a better treatment response for both primary and sec-
ondary effectiveness endpoints in patients enrolled in India.
Overall, 64.9% of patients in the vildagliptin group and 57.3%
in the comparator group achieved an HbA1c reduction of
>0.3% without any predeﬁned tolerability issues, resulting
in an OR of 1.4 (95% CI: 1.07, 1.78; p=0.0134) in favour of
vildagliptin. The OR was 1.6 (95% CI: 1.17, 2.10; p=0.0027) in
favour of vildagliptin compared with that in patients who
were prescribed TZDs. The composite endpoint of HbA1c
<7.0% without hypoglycaemia or weight gain was achieved
by 20.5% and 11.6% of patients in the vildagliptin and com-
parator groups, respectively. The OR was 2.0 (95% CI: 1.32,
2.94; p<0.0009) in favour of vildagliptin, the corresponding
OR was 2.3 (95% CI: 1.40, 3.76; p<0.0010) vs. the patients who
were on TZDs. The adjusted mean reduction in HbA1c was
higher for the vildagliptin group (−1.4%) compared with that
for the comparator group (−1.2%) with a statistically signif-
icant between-treatment difference (−0.3%; p<0.0001). The
change in body weight after 1 year of treatment was −0.7 kg
in the vildagliptin group and +0.5 kg in the comparator group
(between-treatment difference, −1.2 kg; p<0.0001) (Fig. 2). The
between-treatment difference in weight change vs. TZDs was
−1.4 kg (p<0.0001).
The incidence of total AEs was 5.5% (n=69) and 10.3%
(n=31) in the vildagliptin and comparator groups, respec-
tively. The incidence of total AEs in patients who were
prescribed TZDs was 6.0% (n=18). The incidence of hypogly-
caemia was two-fold higher in the comparator group (2.3%,
n=7) comparedwith vildagliptin group (1.1%, n=14); incidence
of severe hypoglycaemia was 0.4% (n=5) in the vildagliptinry Activities; SU sulphonylurea; TZD, thiazolidinedione.
group and 1.0% (n=3) in the comparator group. The incidences
of hypoglycaemia and severe hypoglycaemia were 2.3%
(n=5) and 1.4% (n=3), respectively, in patients who received
TZDs.
4. Discussion
For patients on SU monotherapy, in whom metformin is
contraindicated, there are no (or only limited) speciﬁc rec-
ommendations for the optimal second-line agent. Early
treatment intensiﬁcation in patients with ﬁrst-line SU is warr-
anted to prevent further deterioration of glycaemic control,
as SUs are associated with higher rate of secondary fail-
ure, and several patients are diagnosed at a younger age (in
countries such as India). This exploratory post hoc analysis
of the EDGE study provides new insights into the treat-
ment of patients with T2DM inadequately controlled on SU
monotherapy.
The results of this post hoc analysis showed that the mean
HbA1c at the time of adding the second OAD was high in both
the overall population (8.5%) and the Indian subset (8.7%),
reﬂecting insufﬁcient glycaemic control. There seems to be
a delay in treatment intensiﬁcation with second OAD, despite
the longer T2DM duration (∼6 years) and high baseline HbA1c,
suggesting the presence of clinical inertia. In addition, inten-
siﬁcation of the failing SU therapy was delayed even further
compared with the overall EDGE data. Prospective work tar-
geted at educating physicians and patients regarding early
treatment intensiﬁcation might help improve overall out-
comes [12].
Apart from vildagliptin, the most widely prescribed OAD as
an add-on to SU monotherapy was TZD, particularly in India.
This is logical, as TZDs act by improving insulin resistance
[13], complementing the effect of SUs. However, this combi-
nation is associated with adverse effects like weight gain and
ﬂuid retention [14]. Additionally, caution is suggested when
prescribing TZDs to patients with congestive heart failure [15].After 1 year of treatment, a signiﬁcantly higher propor-
tion (∼50%) of patients achieved a clinicallymeaningful HbA1c
reduction of >0.3% without any tolerability issues with addi-
tion of vildagliptin. This highlights the importance of timely
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Available from: http://www.nice.org.uk (last accessed:
10.08.15).
[4] Indian Council for Medical Research, Guideline for
Management of Type 2 Diabetes, 2005. Available from:pr imary care d iabet
dentiﬁcation of treatment failure and appropriate intensiﬁ-
ation with well-tolerated agents such as DPP-4 inhibitors.
n accordance with the treatment guidelines, which recom-
end maintaining HbA1c <7.0% without hypoglycaemia and
eight gain, the odds for achieving HbA1c <7.0% without
ypoglycaemia and weight gain were almost twice in patients
eceiving vildagliptin vs. comparators. Moreover, the mean
bA1c reductions were signiﬁcantly higher with vildagliptin
elative to comparators. In addition to signiﬁcant HbA1c
eductions and decreased risk of hypoglycaemic events, treat-
ent with vildagliptin also resulted in signiﬁcant weight loss
elative to comparators; this difference was more pronounced
n comparison with TZDs. In general, vildagliptin in compari-
on with comparators was well tolerated, with an overall low
ncidence of AEs (7.0% vs. 8.2%) and hypoglycaemia (0.9% vs.
.2%).
Patients enrolled from India were younger, had lower BMI
nd higher baseline HbA1c when compared with the overall
opulation. A higher proportion of patients from India in the
ildagliptin and comparator groups achieved HbA1c reduc-
ion >0.3% without any tolerability issues when compared
ith the overall group. On the contrary, a lower proportion
f patients from India reached HbA1c <7.0% without any tol-
rability issues. The differences in the results may be possibly
riven by high HbA1c in the Indian subset. The incidence of
Es was low in general and similar across the Indian and over-
ll population.
Several studies have evaluated the efﬁcacy and safety of
PP-4 inhibitors as add-on to SU under randomised and real-
ife settings [16–18]. However, most of the patients enrolled
ere either receiving or received treatment with metformin in
ddition to SU andDPP-4 inhibitor and, none of the studies has
eportedoutcomes for patientswithﬁrst-line SUmonotherapy
or whom metformin is not an option.
Interpretation of the results of this post hoc analysis should
onsider its limitations. The EDGE study was conducted at
time when DPP-4 inhibitors were being launched and was
esigned to assess the effectiveness and safety of vildagliptin
ompared with other OADs (except SGLT-2 inhibitors which
ere not yet approved) under real-life settings. The informa-
ion regarding duration or therapeutic doses of the SU therapy
ere lacking, but based on the baseline HbA1c levels reported,
atients might have been on SUs for a long time and some
ay have even developed resistance to SU-induced hypogly-
aemia. As thiswas a secondary analysis andnot pre-speciﬁed
n the protocol, the results were not adjusted for potential
aseline and demographic confounders. The young age at
iagnosis, low BMI and high baseline HbA1c of the patients
nrolled from India are characteristics of Latent Autoimmune
iabetes in Adults (LADA), however, glutamic acid decarbox-
lase (GAD) autoantibodies were not measured in this real-life
tudy to conﬁrm the presence of LADA. Owing to the real-life
ature of the study, some missing HbA1c and weight data and
nderreporting of AEs (patientswere encouraged to report AEs
oluntarily) might have affected the overall ﬁndings.
In general, this report and any such future reports
n optimisation and intensiﬁcation of the failing ﬁrst-line
U monotherapy may contribute towards an evidence-
ased clinical practice, eventually beneﬁting patients on SU
onotherapy with limited options for intensiﬁcation.0 ( 2 0 1 6 ) 452–458 457
5. Conclusions
In people with T2DM failing on SU monotherapy, vildagliptin
as an add-on therapy resulted in a higher proportion of
patients achieving clinically relevant HbA1c reductions with-
out tolerability issues compared with other OADs. These data
support the use of DPP-4 inhibitors such as vildagliptin in
patientswho require intensiﬁcationof existing SU therapy and
in whom metformin is contraindicated or not tolerated.
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